Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ.

Purpose: To describe the quality assurance (QA) program and early toxicities in the phase III randomized trial BONBIS (NCT00907868) on the role of a localized radiation boost in ductal carcinoma in situ (DCIS).

Materials And Methods: From November 2008 to July 2014, 2004 patients were randomized in arm A (only whole breast radiotherapy, WBRT) and arm B (WBRT + boost). The QA program involved 44 participant centers that performed the dummy run (DR).

[Predictive assays for responses of tumors and normal tissues in radiation oncology].

The impact of curative radiotherapy depends mainly on the total dose delivered homogenously in the target volume. Tumor sensitivity to radiotherapy may be particularly inconstant depending on location, histology, somatic genetic parameters and the capacity of the immune system to infiltrate the tumor. In addition, the dose delivered to the surrounding healthy tissues may reduce the therapeutic ratio of many radiation treatments.

[Individual modification of the dose, volume and fractionation of breast radiotherapy].

Randomized trials demonstrated similar overall survival between mastectomy and breast-conservative surgery followed by adjuvant radiation therapy. Breast-conservative surgery, with adjuvant radiation therapy, with or without neoadjuvant systemic therapy has become the standard of care for women with early or locally advanced breast cancer. Nevertheless, certain cardiac, lung or cutaneous toxicities may alter the long-term body image and the quality of life of a limited number of patients who consider having had "overtreatment" or treatment outside the best knowledge of science.

Assessment of combined use of ArcCheck detector and portal dosimetry for delivery quality assurance of head and neck and prostate volumetric-modulated arc therapy.

Purpose: To assess the efficiency of combined use of ArcCheck detector (AC) and portal dosimetry (PDIP) for delivery quality assurance of head and neck and prostate volumetric-modulated arc therapy.

Materials And Methods: Measurement processes were studied with the Gamma index method according to three analysis protocols. The detection sensitivity to technical errors of each individual or combined measurement processes was studied by inserting collimator, dose and MLC opening error into five head and neck and five prostate initial treatment plans.